Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27255092 | 0.91 | HRH3 (0.31) | HRH3CYP2D6KCNH2 | |
| SCHEMBL21191898 | 0.85 | — | — | |
| SCHEMBL21473019 | 0.80 | HRH3 (0.32) | HRH3CYP2D6KCNH2CHRNA7KDM1A | |
| SCHEMBL20715134 | 0.80 | HRH3 (0.32) | HRH3CYP2D6KCNH2CHRNA7KDM1A | |
| SCHEMBL22874763 | 0.80 | HRH3 (0.39) | HRH3 | |
| SCHEMBL25046185 | 0.78 | HRH3 (0.36) | HRH3CYP2D6KCNH2 | |
| SCHEMBL26846258 | 0.78 | CYP2D6 (0.35) | HRH3CYP2D6 | |
| SCHEMBL21482205 | 0.77 | HRH3 (0.33) | HRH3CYP2D6KCNH2 | |
| SCHEMBL22566191 | 0.77 | HRH3 (0.36) | HRH3CYP2D6KCNH2 | |
| SCHEMBL12909477 | 0.77 | HRH3 (0.33) | HRH3CYP2D6KCNH2CHRNA7KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023161878-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR FOLATE RECEPTOR-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-08-31 | — | — | WO | disclosed |
| WO-2022133285-A1 | MOLECULES AND METHODS RELATED TO TREATMNET OF DISORDERS ASSOCIATED WITH JAK-2 SIGNALING DYSFUNCTION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022081925-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-10766860-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| WO-2020160193-A2 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| US-10392368-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190040043-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-02-07 | — | — | US | disclosed |
| US-10196364-B2 | Pyrimidine carboxamides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180057458-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2018-03-01 | — | — | US | disclosed |
| US-20170210713-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2017-07-27 | — | — | US | disclosed |
| US-9233979-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20150266895-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20070238694-A1 | Purine compounds and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196364-B2 | Pyrimidine carboxamides as sodium channel blockers | CACNA1A, TRPV1, TRPA1 | HRH3 473/4885CYP2D6 408/4885KCNH2 35/4885 |
| US-20070238694-A1 | Purine compounds and methods of use thereof | PNP, ADORA2A, P2RY1 | HRH3 2227/4885CYP2D6 2012/4885KCNH2 3178/4885 |
| US-20190040043-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | JAK3, JAK1, JAK2 | HRH3 977/4885CYP2D6 1682/4885KCNH2 2048/4885 |
| US-20150266895-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK10, MAP3K1 | HRH3 3425/4885CYP2D6 1831/4885KCNH2 4428/4885 |
| US-10392368-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | JAK3, JAK1, JAK2 | HRH3 977/4885CYP2D6 1682/4885KCNH2 2048/4885 |
| US-20170210713-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | CACNA1A, TRPV1, TRPA1 | HRH3 473/4885CYP2D6 408/4885KCNH2 35/4885 |
| US-10766860-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | LOXL2, LOXL1, LOX | HRH3 3039/4885CYP2D6 1111/4885KCNH2 4654/4885 |
| US-20180057458-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | HRH3 3039/4885CYP2D6 1111/4885KCNH2 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.